Kilitch Drugs Q1 FY27: Revenue up nearly 20%, PAT grows 5%

Results View source PDF Explain this filing

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹190.54

prior close

₹181.66

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-4.7% vs market

Pharmaceuticals peers, median of 166sector-0.4%-4.3% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.7+0.1-4.7-0.4-4.3

Next day

-9.4+0.2-9.6-0.3-9.1

-13.9+0.6-14.5-0.5-13.4

-17.1-0.0-17.1-1.3-15.8

-14.7+0.5-15.2-0.8-13.9

-14.5+0.8-15.3-0.4-14.1

-10.2+0.6-10.8-0.9-9.4

15d

-5.0+1.3-6.3+0.0-5.1

+0.2-1.4+1.6-0.1+0.3

+20.7-0.6+21.2-2.8+23.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kilitch Drugs Q1 FY27 standalone: Net sales rose to Rs 4,091 lakhs from Rs 3,412 lakhs, up nearly 20% YoY. Total income up 18% to Rs 4,446 lakhs. Profit after tax rose 5% to Rs 505 lakhs (EPS Rs 1.45). Expenses grew faster than revenue, pressing margins. Consolidated PAT fell to Rs 197 lakhs from Rs 226 lakhs as foreign subsidiary Kilitch Estro Biotech posted a loss of Rs 287 lakhs. Auditors gave a clean limited review.

Likely market impact

Standalone revenue growth healthy but margins under pressure; consolidated dragged by foreign subsidiary losses.